Top 8 Veterinary Prescription Heart and Blood Pressure Medications for Dogs in Canada - 2026 Veterinary Guide to ACE Inhibitors, Beta-Blockers, Diuretics, Vasodilators & Antiarrhythmics with Dosing, Monitoring and Combination Therapy

Vetmedin (pimobendan) is a market leader in canine cardiac care as a positive inotrope and vasodilator frequently used alongside ACE inhibitors to improve clinical outcomes in congestive heart failure. Although not an ACE inhibitor itself, its clear survival and quality-of-life benefits make it a standard complementary therapy to the ACE products listed here, and its established efficacy can reduce downstream treatment costs by stabilizing patients more quickly. Practically, clinicians favor pairing Vetmedin with ACE inhibitors for a combined pharmacologic strategy rather than as a standalone blood-pressure agent.

Fortekor (benazepril) is an ACE inhibitor rather than an ARB, but it remains a widely used, well-studied and generally lower-cost prescription for canine cardiovascular disease and proteinuria. Clinicians frequently choose it as a financially attractive first-line therapy; however, dogs intolerant to ACE inhibitors or those needing direct angiotensin II receptor blockade may benefit more from ARBs like telmisartan, losartan or irbesartan despite their higher cost or compounded status.

Propranolol 10mg is a commonly used small-dose, non-selective beta blocker favored when clinicians require both peripheral and central beta blockade in small dogs, and its low strength facilitates fine dosing adjustments. Its higher lipophilicity relative to atenolol provides different therapeutic effects in some arrhythmic or stress-related indications, though this can also increase the potential for central side effects and monitoring needs. Financially it is typically low-cost per tablet, making it a practical choice for short-term or adjunctive therapy compared with the more specialized and expensive sotalol.

Lasix is the long-standing market leader for acute and chronic diuretic management in dogs because of its rapid, potent loop diuretic effect and widespread veterinary familiarity; it is especially effective for acute pulmonary edema and congestive heart failure. Compared with other agents on this list it offers the lowest acquisition cost per dose and a predictable IV/oral dosing profile, though it lacks the potassium-sparing and RAAS-modifying properties of spironolactone and the longer duration of torsemide.

As a widely recognized, licensed sildenafil product, Viagra 25mg tablets act as the market leader for canine vasodilator therapy because of consistent manufacturing standards, well-characterized pharmacokinetics, and broad clinical availability for treating pulmonary hypertension in dogs. Compared with a compounded amlodipine suspension, Viagra offers stronger regulatory oversight and predictable dosing which can justify higher per-unit cost in cases where stability and standardized potency are priorities.

Diltiazem is a calcium‑channel blocker widely recognized as best‑in‑class for supraventricular tachyarrhythmias and AV nodal rate control in dogs, offering predictable hemodynamic effects and compatibility with other rhythm agents. Compared with amiodarone and sotalol, it is often preferred for atrial‑origin tachyarrhythmias because of a favorable side‑effect profile and cost‑effective generic availability, making it an efficient choice for outpatient management of SVT.

Cardisure flavoured tablets offer a more palatable, cost-competitive pimobendan option tailored to ease administration in picky eaters and small dogs, making it a market leader among flavored generics. Financially it often undercuts brand-name Vetmedin while providing similar active-ingredient benefits, though it may have fewer large-scale clinical studies directly referenced by clinicians compared with the originator brand.

Sildenafil (generic) is the principal pulmonary vasodilator in canine combination cardiac therapy, providing targeted reduction of pulmonary artery pressure and improving exercise tolerance in dogs with pulmonary hypertension. Although generally more expensive than atenolol and sometimes requiring additional monitoring when co-administered, its technical advantage in directly addressing pulmonary vascular resistance makes it a complementary agent to beta-blockers and spironolactone in multi-drug regimens.